Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

• Makoto Tahara,
• Ranee Mehra,
• Kei Muro,
• Bhumsuk Keam,
• Mark Ayers,
• Robin Mogg,
• Razvan Cristescu,
• Jared Lunceford,
• Andrew Albright,
• Jonathan Cheng,
• Barbara Burtness,
• Shilpa Gupta,
• Hyunseok Kang,
• Laura Q M Chow,
• Lingkang Huang,
• Joseph P Eder,
• Jared Weiss,
• Robert I Haddad,
• Tanguy Y Seiwert,
• Iris Gluck

Affiliations

Makoto Tahara

Aff4 grid.272242.30000000121685385National Cancer Center Hospital East Kashiwa Japan

Ranee Mehra

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA

Kei Muro

Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

Bhumsuk Keam

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

Mark Ayers

Aff218 grid.417993.10000000122600793Merck & Co., Inc. West Point PA USA

Robin Mogg

Aff219 grid.417993.10000000122600793Merck & Co., Inc. Kenilworth NJ USA

Razvan Cristescu

Merck & Co, Inc, Kenilworth, New Jersey, USA

Jared Lunceford

Merck & Co, Inc, Kenilworth, New Jersey, USA

Andrew Albright

Merck & Co, Inc, Kenilworth, New Jersey, USA

Jonathan Cheng

Aff244 grid.417993.10000000122600793Merck & Co., Inc. Kenilworth NJ USA

Barbara Burtness

Aff8 grid.47100.320000000419368710Yale University School of Medicine New Haven CT USA

Shilpa Gupta

Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA

Hyunseok Kang

University of California, San Francisco, San Francisco, CA, USA

Laura Q M Chow

Department of Oncology, University of Texas at Austin, Dell Medical School, Austin, Texas, USA

Lingkang Huang

3 Merck & Co., Inc, Kenilworth, New Jersey, USA

Joseph P Eder

Early Drug Development, Yale Cancer Institute, New Haven, Connecticut, USA

Jared Weiss

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA

Robert I Haddad

Department of Medical Oncology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA

Tanguy Y Seiwert

Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA

Iris Gluck

Department of Oncology, Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel